Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Disclosure] Samsung Biologics (207940) – Provisional Performance (Consolidated Financial Results) / 2024-01-24 Disclosures
  • [Disclosure] Jeju Semiconductor(080220) – (Correction) Resolution on Convening of Extraordinary General Meeting of Shareholders / 2026-05-14 Semiconductors
  • [Disclosure] KEPCO (015760 / KEP) – Other Corporate Matters (Voluntary Disclosure) / 2025-11-11 Disclosures
  • [Disclosure] Jusung Engineering (036930) – Setting of Record Date or Period for Closure of Shareholders’ Register / 2024-08-16 Disclosures
  • [Disclosure] Celltrion (068270) – Decision on Bonus Issue (Correction) / 2025-05-28 Bio & Healthcare
  • [Disclosure] Hanwha Ocean (042660) – (Correction) Acquisition of Shares and Equity Securities of Other Corporations / 2025-08-08 Disclosures
  • [Disclosure] Samsung Biologics (207940) – Results of Annual General Meeting of Shareholders / 2025-03-14 Disclosures
  • [Disclosure] Hanwha Systems (272210) – (Correction) Decision on Paid-in Capital Increase / 2025-12-23 Disclosures

[Disclosure] Celltrion (068270) – Notice of Ex-Rights Reference Price / 2026-06-02

Posted on June 2, 2026August 6, 2026 By K-STOCK Editor

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Following Celltrion’s bonus issue, the ex-rights reference price for common stock effective June 4, 2026, has been set at KRW 179,100.

📊 [Key Disclosure Details & Financial Summary]

  • Disclosure Title: Notice of Ex-Rights Reference Price
  • Company Name: Celltrion Co., Ltd.
  • Share Class & Reference Price: Common Stock KRW 179,100
  • Reason: Ex-rights (Bonus Issue)
  • Effective Date: June 4, 2026
  • Regulatory Basis: Article 30 of the Enforcement Rules of the KOSPI Market Business Regulations

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Monitoring Price Adjustments and Respective New Share Listing Dates

This disclosure sets the base opening price for the ex-rights date—the first trading day when shares trade without the right to receive new bonus shares. Because ex-rights adjustments can cause a temporary visual illusion of lower share prices, investors should keep track of the subsequent dilution as new shares enter the market. The final listing schedule for newly issued bonus shares and changes to capital stock can be verified through upcoming additional listing notices or under the ‘Changes in Capital Stock’ section in periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).

📢 Disclaimer & Source Information

Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.

Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Celltrion (068270) – Market Measures for Stock Futures and Options Following Bonus Issue / 2026-06-02
Next Post: [Disclosure] KEPCO (015760 / KEP) – Decision to Convene General Meeting of Shareholders / 2026-06-02

Related Posts

  • [Disclosure] Samsung Biologics (207940) – Measures Such as Prosecution Notice for Breach of Accounting Standards / 2025-02-10 Disclosures
  • [Disclosure] Celltrion (068270) – New Facility Investment (Correction) / 2024-11-12 Disclosures
  • [Disclosure] KEPCO (015760 / KEP) – Investor Relations (IR) Holding Announcement / 2026-02-23 Disclosures
  • [Disclosure] Samsung Biologics (207940) – (Correction) Contract Signings for Supply and Sales / 2026-04-10 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Investor Relations (IR) Holding (Notice) / 2025-03-21 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Outlook on Sales Performance, Etc. (Fair Disclosure) / 2025-01-03 Disclosures
  • [Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in the U.S. / 2024-08-12 Disclosures
  • [Research] SK hynix (000660 / SKHY) – Yuanta | DRAM Inventory · Supplier Pricing Power · Server Demand / 2025-10-29 RESEARCH
  • [Disclosure] Samsung Electronics (005930) – Resolution on Convening of General Meeting of Shareholders / 2026-02-13 Semiconductors
  • [Disclosure] Hyundai Motor (005380) – Reference Price for Interim (Quarterly) Ex-Dividend / 2025-05-28 Disclosures
  • [Disclosure] Hanwha Systems (272210) – Decision on Acquisition of Shares and Equity Securities of Other Corporation / 2025-06-25 Disclosures
  • [Disclosure] Samsung Electronics (005930) – (Correction) Provisional Consolidated Financial Results (Fair Disclosure) / 2025-07-31 Semiconductors
  • [Disclosure] SK Hynix (000660 / SKHY) – Decision on Cash Dividend and Dividend in Kind / 2025-01-23 Semiconductors
  • [Disclosure] Hanwha Ocean (042660) – (Correction) Sales and Supply Contract / 2025-12-04 Disclosures

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme